- Home
- ADXN vs CMMB Comparison
ADXN vs CMMB Comparison
Compare ADXN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | CMMB |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | Switzerland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 10.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ADXN | CMMB |
|---|---|---|
| Price | $7.71 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 8.5K | ★ 57.5K |
| Earning Date | 12-04-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,824.00 | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $1.53 |
| 52 Week High | $12.05 | $8.76 |
Technical Indicators
Market Signals| Indicator | ADXN | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 40.54 |
| Support Level | $7.60 | $1.53 |
| Resistance Level | $8.24 | $1.73 |
| Average True Range (ATR) | 0.59 | 0.14 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 20.70 | 32.31 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.